An open label, phase I/II study to evaluate the safety and efficacy of tenalisib (RP6530), a novel PI3K δ/γ dual inhibitor, given in combination with a histone deacetylase inhibitor, romidepsin, in adult patients with relapsed/refractory T-cell lymphoma.
A single-arm, multicenter, open-label, phase III clinical trial to evaluate the efficacy, safety and pharmacokinetics of once weekly subcutaneous administration of emicizumab in hemophilia A pediatric patients with inhibitors.
A multicenter, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous and/or intravenous PF-06741086 in subjects with severe hemophilia A or B.
A double blind, randomized, vehicle controlled, crossover study to evaluate the safety and efficacy of a topical lotion, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).
A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-cell ALL.